BCL-2 represents a major apoptosis escape mechanism in chronic lymphocytic leukaemia (CLL), allowing the leukaemic cells to evade normal processes that lead to programmed cell death. Venetoclax is a selective inhibitor of BCL-2 and as such has the potential to restore apoptotic mechanisms. In a phase Ib study, presented at EHA 2015, the chemotherapy-free combination of venetoclax and rituximab was evaluated in 49 patients with relapsed CLL.
(BELG J HEMATOL 2015;6(3):98)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
